Statins are considered contraindicated in patients with chronic liver disease.
Dr Shirin Khorashadi and colleagues from California determined the risk of developing hepatotoxicity from statin therapy in hyperlipidemic patients with Hepatitis C.
The investigative team found changes in liver biochemistry values within 12 months.
The team compared these results with baseline in 3 cohorts matched for age, sex, and body mass index.
Group 1 included 166 anti-Hepatitis C virus-positive hyperlipidemic veterans who were initiated on statin therapy.
There were 332 anti-Hepatitis C virus-positive veterans who had not received statin therapy in Group 2.
|Statin therapy discontinuation was similar in Hep C-positive and -negative patients|
|Clinical Gastroenterology & Hepatology|
A further 332 anti-Hepatitis C virus-negative hyperlipidemic veterans initiated on statin therapy were included in Group 3.
An increase in liver biochemistry values was defined as mild-moderate or severe as proposed in a study on statin hepatotoxicity in a non-Hepatitis C population.
The investigators found that in patients with Hepatitis C, statin therapy was associated with a higher incidence of mild-moderate liver biochemistry.
The team noted that values increased compared with those not on statin therapy, but with a lower incidence of severe increases.
Among patients started on statin therapy in Groups 1 and 3, the incidence of mild-moderate liver biochemistry increased.
Severe increases, or discontinuation of statin therapy as a result of hepatotoxicity were similar in Hepatitis C-positive and -negative patients.
Dr Khorashadi's team concluded, “Statin therapy was not associated with a higher risk of severe hepatotoxicity in patients with chronic Hepatitis C, and appeared safe.”